Several TKIs are in adjuvant clinical research for the treatment of HER2-positive early breast cancer (EBC).105 Various HER1/HER2 TKIs, pan-HER TKIs, and dual HER2/VEGF TKIs are in different stages of advance clinical practice.15 Here, ERBB2 is linked to breast carcinoma.